• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自制药枣养荣颗粒治疗靶向药物相关性皮肤干燥症随机双盲对照研究。

Application of Zizao Yangrong Granules for Treating Targeted Drugs-Related Skin Xerosis: A Randomized Double-Blinded Controlled Study.

机构信息

Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China.

Beijing University of Chinese Medicine, Beijing, China.

出版信息

Integr Cancer Ther. 2020 Jan-Dec;19:1534735420924832. doi: 10.1177/1534735420924832.

DOI:10.1177/1534735420924832
PMID:32567372
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7309378/
Abstract

Dermatologic toxicities are the most common side effects associated with the targeted drugs epidermal growth factor receptor inhibitors (EGFRIs), in which xerosis commonly complicated by pruritus severely disturbs the quality of life. The study has observed the curative effect of Zizao Yangrong granules (ZYG) from Chishui Xuanzhu in the treatment of EGFRIs-related xerosis and pruritus, as well as evaluating the safety of the prescription. Patients (n = 68) who had xerosis after using EGFRIs were enrolled and then randomly divided into the treatment group and control group, respectively, receiving ZYG and placebo granules combined with vitamin E ointment. The intervention lasted 4 weeks. Changes in xerosis and pruritus were observed, and blood routine examination as well as liver and kidney function . . A total of 66 out of 68 patients finished the study with 34 patients . The effective rates of xerosis among the treatment group and control group were 84.8% and 69.7% after 2 weeks' treatment ( < .05), while they were 84.8% and 75.8% after 4 weeks' treatment ( < .05). The patients in the experimental group had better quality of life than that in the control group ( = .045). ZYG can effectively improve the skin dryness associated with EGFRIs, and significantly improve the quality of life of patients with good safety; however, larger randomized controlled trials are needed to verify these findings.

摘要

皮肤毒性是靶向药物表皮生长因子受体抑制剂(EGFRIs)最常见的副作用,其中干燥症常伴有严重瘙痒,严重影响生活质量。本研究观察了赤水玄珠自制药滋燥养荣颗粒(ZYG)治疗 EGFRIs 相关干燥症和瘙痒的疗效,并评价了该处方的安全性。纳入使用 EGFRIs 后出现干燥症的患者(n=68),随机分为治疗组和对照组,分别给予 ZYG 和安慰剂颗粒联合维生素 E 软膏治疗。干预持续 4 周。观察干燥症和瘙痒的变化,以及血常规、肝肾功能。共 68 例患者完成研究,其中治疗组 34 例。治疗 2 周后,治疗组和对照组的干燥症有效率分别为 84.8%和 69.7%(<0.05),治疗 4 周后分别为 84.8%和 75.8%(<0.05)。实验组患者的生活质量优于对照组(=0.045)。ZYG 能有效改善 EGFRIs 相关皮肤干燥,显著提高患者生活质量,且安全性良好;但需要更大规模的随机对照试验来验证这些发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37da/7309378/72accd0c71be/10.1177_1534735420924832-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37da/7309378/a25b3080f7d9/10.1177_1534735420924832-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37da/7309378/72accd0c71be/10.1177_1534735420924832-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37da/7309378/a25b3080f7d9/10.1177_1534735420924832-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37da/7309378/72accd0c71be/10.1177_1534735420924832-fig2.jpg

相似文献

1
Application of Zizao Yangrong Granules for Treating Targeted Drugs-Related Skin Xerosis: A Randomized Double-Blinded Controlled Study.自制药枣养荣颗粒治疗靶向药物相关性皮肤干燥症随机双盲对照研究。
Integr Cancer Ther. 2020 Jan-Dec;19:1534735420924832. doi: 10.1177/1534735420924832.
2
[Treatment of EGFRIs-related Skin Adverse Reactions by Zhiyang Pingfu Lotion].[止痒平肤洗剂治疗表皮生长因子受体抑制剂相关皮肤不良反应]
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2017 Feb;37(2):149-154.
3
Topical Zhiyang Pingfu Liquid for Moderate to Severe Skin Rash Associated With EGFRIs: A double-blinded randomized controlled trial.芷阳平复液治疗 EGFRIs 相关中重度皮疹的多中心、随机、双盲对照研究
Integr Cancer Ther. 2022 Jan-Dec;21:15347354221140409. doi: 10.1177/15347354221140409.
4
Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study.一种保湿剂治疗透析患者伴干燥性瘙痒的疗效:一项多中心、开放性、随机验证研究。
J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26.
5
Efficacy of an emollient containing diethylene glycol/dilinoleic acid copolymer for the treatment of dry skin and pruritus in patients with senile xerosis.一种含有二甘醇/二亚油酸共聚物的润肤剂治疗老年皮肤干燥症患者皮肤干燥和瘙痒的疗效。
J Cosmet Dermatol. 2017 Dec;16(4):e37-e41. doi: 10.1111/jocd.12332. Epub 2017 Mar 30.
6
Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.针对 EGFR、BRAF 和 CTLA-4 的抗癌药物引起的瘙痒。
Dermatol Ther. 2013 Mar-Apr;26(2):135-48. doi: 10.1111/dth.12027.
7
Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.靶向肿瘤治疗引起的丘疹脓疱性皮疹及其他皮肤副作用:一项回顾性研究
Cutan Ocul Toxicol. 2019 Sep;38(3):261-266. doi: 10.1080/15569527.2019.1594874. Epub 2019 May 7.
8
Xerosis and pruritus as major EGFRI-associated adverse events.皮肤干燥和瘙痒是与表皮生长因子受体抑制剂(EGFRI)相关的主要不良事件。
Support Care Cancer. 2016 Feb;24(2):513-521. doi: 10.1007/s00520-015-2781-y. Epub 2015 Jun 27.
9
Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.表皮生长因子受体抑制剂相关皮肤不良反应的预防和治疗。
Curr Opin Oncol. 2011 Jul;23(4):343-51. doi: 10.1097/CCO.0b013e3283474063.
10
Effects of Colloidal Oatmeal Lotion on Symptoms of Dermatologic Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors.胶体燕麦片洗剂对表皮生长因子受体抑制剂所致皮肤毒性症状的影响。
Adv Skin Wound Care. 2017 Jan;30(1):27-34. doi: 10.1097/01.ASW.0000505611.28732.ba.

本文引用的文献

1
Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis.西妥昔单抗和帕尼单抗在转移性结直肠癌治疗中的不同毒性:一项系统评价和荟萃分析
Oncology. 2018;94(4):191-199. doi: 10.1159/000486338. Epub 2018 Jan 23.
2
Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study.替沃扎尼联合厄洛替尼对比厄洛替尼单药用于 EGFR 突变型 NSCLC:III 期 MARQUEE 研究的探索性分析。
J Thorac Oncol. 2018 Jun;13(6):849-854. doi: 10.1016/j.jtho.2017.12.009. Epub 2017 Dec 27.
3
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
4
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.达克替尼对比吉非替尼作为 EGFR 突变阳性非小细胞肺癌患者的一线治疗(ARCHER 1050):一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.
5
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.阿法替尼与吉非替尼治疗表皮生长因子受体(EGFR)突变阳性的晚期非小细胞肺癌患者:IIb期LUX-Lung 7试验的总生存数据
Ann Oncol. 2017 Feb 1;28(2):270-277. doi: 10.1093/annonc/mdw611.
6
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.厄洛替尼对比吉非替尼用于治疗伴有表皮生长因子受体(EGFR)突变的晚期非小细胞肺癌的III期随机对照试验。
Br J Cancer. 2017 Feb 28;116(5):568-574. doi: 10.1038/bjc.2016.456. Epub 2017 Jan 19.
7
Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients.吉非替尼的皮肤副作用及经表皮水分流失:11例患者的研究
Dermatol Ther (Heidelb). 2017 Mar;7(1):133-141. doi: 10.1007/s13555-016-0163-0. Epub 2016 Dec 21.
8
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.奥希替尼或铂类培美曲塞用于治疗表皮生长因子受体T790M阳性肺癌
N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.
9
Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.表皮生长因子受体抑制剂引发的皮肤事件:患者声音缺失的问题。
Support Care Cancer. 2017 Feb;25(2):651-660. doi: 10.1007/s00520-016-3419-4. Epub 2016 Oct 7.
10
Herb pairs containing Angelicae Sinensis Radix (Danggui): A review of bio-active constituents and compatibility effects.含当归的药对:生物活性成分与配伍效应综述
J Ethnopharmacol. 2016 Apr 2;181:158-71. doi: 10.1016/j.jep.2016.01.033. Epub 2016 Jan 22.